Ozempic Slows Kidney Disease, Novo Nordisk Study Finds
By Dominic Chopping
Novo Nordisk's Ozempic drug slows the progression of chronic kidney disease and cuts the risk of kidney failure, heart attack, stroke and death in patients with type 2 diabetes, detailed results of a long-term trial showed Friday.
Headline results from the multiyear study of semaglutide, which is marketed as Ozempic to treat diabetes, were announced in March and showed the drug cuts the risk of kidney disease-related events in diabetic patients by 24%.
But detailed findings presented at a medical conference in Stockholm on Friday and published in the New England Journal of Medicine show that the rate of kidney function decline slowed significantly in patients who took semaglutide versus placebo, while the risk of a major heart problem fell by 18% and risk of death from any cause fell 20%.
Novo Nordisk said in October that it had stopped the trial early due to successful results. Ozempic is approved to treat diabetes but the company expects to file for a label expansion in the U.S. and EU this year.
Write to Dominic Chopping at dominic.chopping@wsj.com
(END) Dow Jones Newswires
May 24, 2024 07:55 ET (11:55 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Six Sports Betting and iGaming Stocks Trading at a Discount
-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations